Katsuyuki Furuta
Wakayama, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Docetaxel plus ramucirumab immediately after immunotherapy in advanced NSCLC: A phase II study (DRUN).
Journal: Lung cancer (Amsterdam, Netherlands)
Published: May 05, 2026
Association between initial treatment response and prognosis in acute exacerbations of idiopathic pulmonary fibrosis treated with steroid pulse therapy.
Journal: Respiratory medicine
Published: February 05, 2025
Mannitol versus furosemide in patients with thoracic malignancies who received cisplatin-based chemotherapy using short hydration: A randomized phase II trial.
Journal: Cancer medicine
Published: November 06, 2023
A Phase II Study of High-Flow Nasal Cannula for Relieving Dyspnea in Advanced Cancer Patients.
Journal: Journal of pain and symptom management
Published: August 10, 2023
Prognostic impact of cytokines and chemokines in bronchoalveolar lavage fluid on acute exacerbation of fibrosing interstitial lung disease.
Journal: Respiratory medicine
Published: June 26, 2023
Pre-treatment serum protein levels predict survival of non-small cell lung cancer patients without durable clinical benefit by PD-1/L1 inhibitors.
Journal: Cancer immunology, immunotherapy : CII
Published: May 04, 2021
Chemotherapy plus atezolizumab for a patient with small cell lung cancer undergoing haemodialysis: a case report and review of literature.
Journal: Respirology case reports
Published: March 06, 2021
Comparison of Systemic Inflammatory Response Syndrome and quick Sequential Organ Failure Assessment scores in predicting bacteremia in the emergency department.
Journal: Acute medicine & surgery
Published: January 20, 2021
CD24, not CD47, negatively impacts upon response to PD-1/L1 inhibitors in non-small-cell lung cancer with PD-L1 tumor proportion score < 50.
Journal: Cancer science
Published: August 20, 2020
Immune-Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non-Small Cell Lung Cancer.
Journal: The oncologist
Published: April 17, 2019
Showing 1-10 of 10
Last Updated: 09/26/2026